After the closing bell on Wednesday, Solta Medical Inc. (SLTM) announced that the U.S. Food and Drug Administration (FDA) approved its device to clear pigmentation and other superficial skin conditions.   The device, called the Fraxel re:store Dual Laser System, can be used both on the face and large body areas to clear pigmentation through a single treatment.   Solta has already received approval for the device with 1550 nanometer (nm) wavelength for skin resurfacing and treatment of pigmented lesions and certain other dermatological conditions.   The present FDA 510(k) clearance is for the Fraxel 1927 nm laser for dermatological procedures requiring the coagulation of soft tissue. Prior to its approval, laser skin resurfacing procedures were largely limited to the face. The approval of the new 1927 nm wavelength increases the areas of the body that physicians can treat, which are further indications of Solta's continued efforts to ...

EPOD Solar Canada Executes Letter of Intent with DayStar Technologies nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp; - EPOD Solar, Inc. U.S. (EPDS.OB) Transfers Rights to Purchase EPOD Solar Canada Assets and Stock to DayStar Technologies September 21, 2009 - KELOWNA, BC ndash; (MARKETWIRE) ndash; EPOD Solar Canada, a vertically integrated manufacturer of thin-film solar modules that develops, owns and operates solar parks throughout Europe and North America (ldquo;EPOD Solarrdquo;), announced today that it has executed a letter of intent (ldquo;Letter of Intentrdquo;) with DayStar Technologies, Inc.,, a developer of solar photovoltaic products based on CIGS thin-film deposition technology (ldquo;DayStarrdquo;), regarding a proposed transaction or series of transactions (collectively, the ldquo;Transactionrdquo;) intended to result in the combination of the businesses of EPOD and DayStar. Upon successful completion of negotiations and due diligence, the parties intend to sign definitive agreements and complete the Transaction as soon as practicable. The consummation of the Transaction will be subject to making ...

Headquartered in Hayward, California, Aradigm Corp. engages in developing inhalation drug products that enhance the quality of life of patients with severe pulmonary disease. Founded in 1991, the company has a team of scientists, engineers, and clinical experts who have been at the forefront of development of advanced inhalation delivery products.

Aradigm Corp.’s team pioneered the AERx® iDMS pulmonary delivery of insulin used in Phase 3 clinical trials conducted by their partner Novo Nordisk. Today, with experience and expertise in inhalation delivery, Aradigm is positioning their company to develop a portfolio of their own products to treat patients with severe respiratory diseases. The company’s current pipeline includes products undergoing development by Aradigm, or in partnerships with others, for the treatment of cystic fibrosis, inhalation anthrax, and pulmonary arterial hypertension. Aradigm Corp. is also investigating the use of their technology for tobacco smoking cessation therapy.

Aradigm’s AERx pulmonary drug delivery platform demonstrated

...

February 18, 2009 ndash; Analyst Comments ndash; Cowenrsquo;s Rob Stone weighed in on Suntechrsquo;s (NYSE:STP) Q4 and FY08 results this morning, reiterating an OUTPERFORM rating on the stock, while Pacific Crestrsquo;s March Bachman thinks OptiSolar could be an attractive take-out target. Suntech reported a Q4 loss of $65.9 million, or $0.42 per share, compared with earnings of $50.6 million, or $0.29 per share for the same period last year. Revenue for the quarter increased 4.2% to $414.4 million. For FY08, net income declined to $111 million, or $0.66 per share, compared to $171.3 million, or $1.02 per share for FY07. Revenue for the year increased 43% to $1.92 billion. Management guided Q1 revenue to a range of $340 to $380 million, with gross margins between 12% to 15% and its FY09 shipments targeted at exceeding 800MW. It expects PV cell production capacity to remain at about 1GW for the year. Stone ...